WS1.1 The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation, the KONNECTION study

WS1.1 The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation, the KONNECTION study K. De Boeck1, A. Munck2, S. Walker3, A. Faro4, P. Hiatt5, J. Chan6, G. Gilmartin6, on behalf of the VX12-770-111 (KONNECTION) Study Group. 1University Hospital Gasthuisberg, Leuven, Belgium; 2University Hospital Robert Debre, Paris, France; 3Emory University, Atlanta, United States; 4Washington University School of Medicine, St. Louis, United States; 5Baylor College of Medicine, Houston, United States; 6Vertex Pharmaceuticals Incorporated, Boston, United States